New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
08:12 EDTHRTXHeron Therapeutics reports Q4 EPS (75c), consensus (53c)
The company said "Net loss was higher in the FY13 quarter primarily due to increased spending related to manufacturing development expenses and higher personnel costs, including stock compensation expense."
News For HRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2015
08:44 EDTHRTXHeron Therapeutics management to meet with Brean Capital
Subscribe for More Information
July 23, 2015
08:08 EDTHRTXHeron Therapeutics initiates second Phase 2 HTX-011 trial
Heron Therapeutics announced that it has initiated a second Phase 2 clinical trial of HTX-011. HTX-011, which utilizes Heronís proprietary Biochronomer drug delivery technology, is a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for the prevention of post-operative pain. The placebo-controlled, dose-finding, Phase 2 clinical trial in approximately 60 patients undergoing inguinal hernia repair will evaluate the efficacy and safety of HTX-011, containing 200 mg or 400 mg of bupivacaine combined with meloxicam, compared to placebo. HTX-011 is also currently being evaluated in a placebo-controlled, dose-finding, Phase 2 clinical trial in patients undergoing bunionectomy. In a previously completed, placebo-controlled, Phase 1 clinical trial, HTX-011 achieved the desired pharmacokinetic profile for both bupivacaine and meloxicam, with therapeutically relevant plasma bupivacaine levels sustained for 2-3 days.
July 20, 2015
08:03 EDTHRTXHeron resubmits SUSTOL NDA to FDA
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use